Aspen Pharmacare (APN) settled its mRNA manufacturing dispute, with the counterparty agreeing to pay €25m (≈R500m) by 1 December 2025. The full and final settlement concludes the protracted contractual issue, providing a modest cash inflow and improved clarity on earnings.
Click here to read the SENS